# A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

> **NCT02013830** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT02013830
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013830, "A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02013830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*